The Role of Somatic Mutation in Hereditary Hemorrhagic Telangiectasia Pathogenesis
Journal of Clinical Medicine · 24.06.2025 · 14 (13) · 4479
DOI: 10.3390/jcm14134479 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.06.2025. Verfasst von Evon DeBose-Scarlett und 1 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
Historically, the factor(s) that stimulate vascular malformation genesis in hereditary hemorrhagic telangiectasia (HHT) has been hotly debated. Once heterozygous loss-of-function germline mutations in ENG, ACVRL1, or SMAD4 were discovered in individuals with HHT, haploinsufficiency, a 50% reduction in the encoded protein, was proposed as the molecular mechanism of HHT. However, the focal and discrete nature of HHT-associated vascular malformations suggested to others that vascular malformation genesis requires an additional, local trigger. In this review, we discuss the evidence for the Knudsonian two-hit mutation mechanism of vascular malformation pathogenesis in HHT, where the inherited, heterozygous mutation is augmented by an acquired somatic mutation in the remaining normal copy of the gene. We consider the mechanisms of HHT–vascular malformation development in the broader context of the emerging role of somatic mutations in both sporadic and inherited vascular malformations. We discuss different mechanisms of biallelic gene inactivation in HHT, difficulties with the detection of all possible mechanisms of biallelic inactivation, and issues related to the somatic mosaic nature of the lesion. We then discuss the critical importance of non-genetic factors on the pathogenesis of HHT-associated vascular malformations. Finally, we discuss the implications of the two-hit mutation mechanism for the design of novel treatments for HHT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.
Förderung
- NINDS NIH HHS
Zitieren
APA
DeBose-Scarlett, E., & Marchuk, D. A. (2025). The Role of Somatic Mutation in Hereditary Hemorrhagic Telangiectasia Pathogenesis. Journal of Clinical Medicine, 14(13), 4479. https://doi.org/10.3390/jcm14134479
Vancouver
DeBose-Scarlett E, Marchuk DA. The Role of Somatic Mutation in Hereditary Hemorrhagic Telangiectasia Pathogenesis. Journal of Clinical Medicine. 2025;14(13):4479. doi:10.3390/jcm14134479
BibTeX
@article{DeBoseScarlett2025,
author = {DeBose-Scarlett, Evon and Marchuk, Douglas A},
title = {The Role of Somatic Mutation in Hereditary Hemorrhagic Telangiectasia Pathogenesis},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {13},
pages = {4479},
doi = {10.3390/jcm14134479}
}
EUVIMED